| Name | Title | Contact Details |
|---|---|---|
Michael Hellerstein |
VP Product Development | Profile |
Jean-Cosme Dodart |
SVP, Preclinical R&D | Profile |
Neha Anand |
Director Talent Acquisition | Profile |
Kate Surdez |
Head of Human Resources | Profile |
Kate Surdez |
Head of Human Resources | Profile |
Bioscience, Inc. is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
PCI Pharma Services is a global leader in Contract Development and Manufacturing Organization (CDMO) services, offering integrated solutions for drug development, manufacturing, and packaging. The company focuses on innovation and patient-centric approaches, supporting pharmaceutical and biopharmaceutical companies at various stages of drug development and commercialization. With 30 Good Manufacturing Practice (GMP) facilities across seven countries, PCI employs over 4,300 people dedicated to delivering life-changing therapies. The company provides a comprehensive range of services, including drug development and manufacturing for various dosage forms, advanced drug delivery systems, and complex packaging solutions. PCI also manages storage, distribution, and logistics to support the pharmaceutical supply chain and offers clinical trial supply chain management. Committed to growth, PCI has made significant investments, including a $100 million expansion in New England to enhance its global capacity and capabilities.
Quintiles is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.
Carmot Therapeutics, Inc. is a biotech company focused on the discovery of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation. Carmot`s vision is to become a leader in drug discovery by unlocking novel therapeutic target space not currently accessible to conventional small molecule technologies.